후성유전학 약물 및 진단 기술 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global epigenetics drugs and diagnostic technologies market size is expected to reach USD 126.50 Billion in 2034 from USD 21.19 Billion in 2025, growing at a CAGR of 21.96% during 2026-2034.This market is advancing as researchers increasingly investigate epigenetic mechanisms that influence gene activity without changing the underlying DNA sequence. Epigenetics plays an important role in cellular function, development, and disease, including certain cancers and other medical conditions. Epigenetics drugs are designed to modify specific biological processes involved in gene regulation, while diagnostic technologies help identify epigenetic changes that may provide information about disease characteristics. Growing interest in precision medicine and molecular diagnostics is encouraging pharmaceutical companies and research institutions to develop therapies and testing methods based on epigenetic mechanisms.

Market growth is driven by advances in molecular biology, increasing investment in drug discovery, and the expanding use of advanced diagnostic technologies. Researchers are investigating compounds that influence DNA methylation and histone modification, particularly in oncology and selected other therapeutic areas. Diagnostic developers are exploring epigenetic biomarkers for disease classification, prognosis, and treatment response assessment. Improvements in sequencing, methylation analysis, and laboratory automation are helping researchers investigate epigenetic patterns with greater detail. Collaborations among pharmaceutical companies, biotechnology firms, and academic institutions are also supporting the identification of new therapeutic targets and the development of diagnostic methods.

The future prospects of this market will depend on clinical research outcomes, biomarker validation, and the development of safer and more effective epigenetic therapies. Advances in multi-omics analysis and artificial intelligence may help researchers interpret complex epigenetic data and identify clinically meaningful patterns. Improved diagnostic platforms could support more precise disease classification and patient selection for specific treatments. However, challenges involving biological complexity, off-target effects, clinical validation, and regulatory approval remain significant. Continued research into disease mechanisms and stronger evidence linking epigenetic findings to clinical outcomes will be important for expanding the practical applications of these technologies.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Technology

• DNA Methylation
• Histone Acetylation
• Large Non-Coding RNA
• MicroRNA Modification
• Chromatin Structures

By Application

• Oncology (Solid Tumors, Liquid Tumors)
• Non-Oncology (Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Other Applications)

By End-User

• Hospitals & Clinics
• Diagnostic Centers
• Other End Users

COMPANIES PROFILED

• Eisai, Otsuka Pharmaceutical, Bristol Myers Squibb, AbbVie, AstraZeneca, GSK, Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Merck KGaA, Novartis, Pfizer, Agilent Technologies, Zymo Research, Diagenode, Active Motif, EpigenDx, Chroma Medicine, EpiCypher

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. DNA Methylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Histone Acetylation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Large Non-Coding RNA Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. MicroRNA Modification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Chromatin Structures Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology (Solid Tumors, Liquid Tumors) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-Oncology (Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases, Other Applications) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Spain
  • 7.3.9 Russia
  • 7.3.10 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 China
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 India
  • 7.4.8 Australia
  • 7.4.9 South East Asia
  • 7.4.10 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Eisai
  • 9.2.2 Otsuka Pharmaceutical
  • 9.2.3 Bristol Myers Squibb
  • 9.2.4 AbbVie
  • 9.2.5 AstraZeneca
  • 9.2.6 GSK
  • 9.2.7 Roche
  • 9.2.8 Thermo Fisher Scientific
  • 9.2.9 Illumina
  • 9.2.10 QIAGEN
  • 9.2.11 Merck KGaA
  • 9.2.12 Novartis
  • 9.2.13 Pfizer
  • 9.2.14 Agilent Technologies
  • 9.2.15 Zymo Research
  • 9.2.16 Diagenode
  • 9.2.17 Active Motif
  • 9.2.18 EpigenDx
  • 9.2.19 Chroma Medicine
  • 9.2.20 EpiCypher